儿科年龄的阳性失动症:一个系统的审查
Giulia Pisanò1, Martina Gnazzo1, Giulia Sigona1
1Child Neurology and Psychiatry Unit, Dipartimento Materno-Infantile, Presidio Ospedaliero Santa Maria Nuova, AUSL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Journal of clinical medicine
|September 13, 2025
概括
遗传因素显著影响儿科帕洛克斯系统性运动障碍 (PDs),这是一个罕见的运动障碍. 早期的基因测试和基因型导向治疗,特别是PRRT2突变的通道阻断剂,改善了结果.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 儿科 儿科 儿科
背景情况:
- 性动症 (PDs) 是儿童罕见的偶发性运动障碍,由于与重叠,经常被误诊.
- 遗传因素对于理解PD异质性和指导儿童群体治疗至关重要.
- 本综述侧重于儿科PD的遗传基础和临床谱.
研究的目的:
- 系统地审查儿科PD,重点关注遗传原因,临床特征和治疗策略.
- 分析基因型-治疗相关性,以有效管理儿科PD.
- 提供关于儿科PD的当前知识的全面概述.
主要方法:
- 从2014年至2025年使用PubMed.Med的系统文献综述.
- 包括确诊或怀疑PD的儿科患者 (0-18岁) 和遗传数据.
- 提取人口统计数据,PD亚型,发病年龄,遗传发现和治疗疗效.
主要成果:
- 有112项研究分析了605名儿科患者,其中帕洛克西斯马尔基内斯基因失动症 (PKD) 是最常见的.
- 在38个基因中,基因诊断在83.5% (505名患者) 中得到证实;PRRT2,SLC2A1和ADCY5是最常见的.
- 通道阻断剂 (例如,卡巴马泽平) 在基因定义的PD中显示出高效率 (59.7%),特别是PRRT2阳性病例.
结论:
- 儿科PD具有显著的临床和遗传异质性,强调需要全面的诊断方法.
- PRRT2突变是主要的遗传原因,但类基因正在出现.
- 基因型驱动的管理,包括针对ADCY5和SLC2A1变异的特定疗法,对于改善预后至关重要.
相关概念视频
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
01:24Parkinson's Disease: Treatment
987
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
987
01:15Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K